Collegium Pharmaceutical (COLL) Total Non-Current Liabilities (2018 - 2026)
Collegium Pharmaceutical (COLL) posted quarterly Total Non-Current Liabilities of $1.4 billion for Q4 2025, down 5.47% year-over-year from $1.4 billion in Q4 2024, and up 1.7% quarter-over-quarter from $1.3 billion in Q3 2025.
Collegium Pharmaceutical (COLL) Total Non-Current Liabilities (2018 - 2026) Analysis & Trends
Collegium Pharmaceutical's Total Non-Current Liabilities history runs 4 years deep, the most recent figure standing at $1.4 billion for Q4 2025.
- In Q4 2025, Total Non-Current Liabilities fell 5.47% year-over-year to $1.4 billion; the TTM figure through Dec 2025 stood at $1.4 billion (down 5.47% YoY), while the FY2025 annual figure was $1.4 billion, down 5.47% from the prior year.
- Total Non-Current Liabilities for Q4 2025 stood at $1.4 billion, up from $1.3 billion in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $1.4 billion in Q4 2024, with the low at $947.9 million in Q4 2023.
- The 3-year median for Total Non-Current Liabilities is $1.4 billion (2025), against an average of $1.3 billion.
- The sharpest annual moves came in 2024 and 2025: Total Non-Current Liabilities surged 51.24% in 2024, then dropped 5.47% in 2025.
- Collegium Pharmaceutical's Total Non-Current Liabilities stood at $947.9 million in 2023, then soared by 51.24% to $1.4 billion in 2024, then dropped by 5.47% to $1.4 billion in 2025.
- Business Quant data shows COLL's Total Non-Current Liabilities at $1.4 billion in Q4 2025, $1.3 billion in Q3 2025, and $1.4 billion in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.85 Bn | 42.88 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 43.02 Bn | 39.37 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 31.47 Bn | 29.79 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.59 Bn | 22.79 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.53 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.45 Bn | 15.06 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | 334.00 Mn |
| 10 | Collegium Pharmaceutical | 894.62 Mn | 745.30 Mn | 110.29 Mn | 1.70 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.79 Bn |
| Dec 31, 2025 | 1.36 Bn |
| Sep 30, 2025 | 1.33 Bn |
| Jun 30, 2025 | 1.36 Bn |
| Mar 31, 2025 | 1.40 Bn |
| Dec 31, 2024 | 1.43 Bn |
| Sep 30, 2024 | 1.40 Bn |
| Dec 31, 2023 | 947.88 Mn |
| Dec 31, 2018 | 198.98 Mn |
| Sep 30, 2018 | 290.90 Mn |
| Jun 30, 2018 | 276.20 Mn |
| Mar 31, 2018 | 261.73 Mn |